Karbinal® ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of seasonal and perennial allergic rhinitis.
Unique Features of Karbinal ER
Read more about the dosing and administration of Karbinal ER.

With Karbinal ER, you get the convenience of twice-daily dosing

Karbinal ER— The 12-hour oral suspension carbinoxamine providing convenient, twice-daily dosing2

12-hour dosing
Child-friendly liquid formulation
Strawberry-banana Flavored
Broad indications and symptom relief
Dosing examples for pediatric patients ages 2-11 years2
  • Using weight-based formula of 0.2 to 0.4 mg/kg/day2
Children 2-11 years of age (approximately 0.2 to 0.4 mg/kg/day):
  • 2 to 3 years – 3.75 mL to 5 mL (3 mg to 4 mg) orally every 12 hours
  • 4 to 5 years – 3.75 mL to 10 mL (3 mg to 8 mg) orally every 12 hours
  • 6 to 11 years – 7.5 mL to 15 mL (6 mg to 12 mg) orally every 12 hours
Adults and adolescents 12 years of age and older:
  • 7.5 mL to 20 mL (6 mg to 16 mg) orally every 12 hours
Advise patients to measure Karbinal ER with an accurate milliliter measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. Shake Karbinal ER well before use.
Bottle of Karbinal ER — Strawberry-banana flavor, extended-release oral suspension
The dosage of Karbinal ER should be individualized based on the severity of the condition and the response of the patient. Start with lower doses and increase as needed and tolerated.
Reference: 2. Karbinal ER Prescribing Information. Englewood, CO Aytu BioPharma, Inc. 2021.
Already picked up your Karbinal ER at the pharmacy?
Get Started
Already have
a prescription for
Karbinal ER?
Download our Savings Offer

IMPORTANT SAFETY INFORMATION

Karbinal ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of:

  • Seasonal and perennial allergic rhinitis
  • Vasomotor rhinitis
  • Allergic conjunctivitis due to inhalant allergens and foods
  • Mild, uncomplicated allergic skin manifestations of urticaria and angioedema
  • Dermatographism
  • As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled
  • Amelioration of the severity of allergic reactions to blood or plasma

Contraindications

  • Children younger than 2 years of age because deaths have been reported in this age group.
  • Patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Karbinal ER.
  • Patients taking monoamine oxidase inhibitors (MAOIs). Do not use Karbinal ER in patients who are taking MAOIs, which prolong and intensify the anticholinergic (drying) effects of antihistamines.

Warnings and Precautions

  • Pediatric Mortality: Deaths have been reported in children less than 2 years of age who were taking carbinoxamine-containing products; therefore, Karbinal ER is contraindicated in children younger than 2 years of age.
  • Somnolence and Impaired Mental Alertness: Karbinal ER may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Karbinal ER. Avoid concurrent use of Karbinal ER with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur.
  • Concomitant Medical Conditions: Karbinal ER has anticholinergic (atropine-like) properties and, therefore, should be used with caution in patients with: increased intraocular pressure, narrow angle glaucoma, hyperthyroidism, cardiovascular disease, hypertension, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction.
  • Allergic Reactions due to Sulfites, including Anaphylaxis: Karbinal ER contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic individuals.
  • Lactation: Advise women breastfeeding is not recommended during treatment with Karbinal ER.

Adverse Reactions

The most frequent adverse reactions include; sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. In clinical use, younger children and older adults may be particularly sensitive to adverse reactions.